vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and GAXOS.AI INC. (GXAI). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× Applied Therapeutics, Inc.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -1899.0%, a 1821.8% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 719.7%).
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
APLT vs GXAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.2M |
| Net Profit | $-19.0M | $-957.9K |
| Gross Margin | — | — |
| Operating Margin | -1675.8% | -99.0% |
| Net Margin | -1899.0% | -77.2% |
| Revenue YoY | 719.7% | 94996.3% |
| Net Profit YoY | 72.3% | -15.1% |
| EPS (diluted) | $-0.13 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2M | ||
| Q3 25 | $1.0M | $498.3K | ||
| Q2 25 | $0 | $171.0K | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $-1.0K | — | ||
| Q2 24 | $144.0K | $0 | ||
| Q1 24 | $190.0K | — | ||
| Q4 23 | $-667.0K | — |
| Q4 25 | — | $-957.9K | ||
| Q3 25 | $-19.0M | $-1.0M | ||
| Q2 25 | $-21.3M | $-749.4K | ||
| Q1 25 | $-21.8M | — | ||
| Q4 24 | $44.0M | — | ||
| Q2 24 | $2.9M | $-809.2K | ||
| Q1 24 | $-83.9M | — | ||
| Q4 23 | $-37.7M | — |
| Q4 25 | — | -99.0% | ||
| Q3 25 | -1675.8% | -263.9% | ||
| Q2 25 | — | -574.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | 3302300.0% | — | ||
| Q2 24 | -14194.4% | — | ||
| Q1 24 | -11101.6% | — | ||
| Q4 23 | 3149.3% | — |
| Q4 25 | — | -77.2% | ||
| Q3 25 | -1899.0% | -201.0% | ||
| Q2 25 | — | -438.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | -4400700.0% | — | ||
| Q2 24 | 2012.5% | — | ||
| Q1 24 | -44177.9% | — | ||
| Q4 23 | 5649.0% | — |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | $-0.13 | $-0.14 | ||
| Q2 25 | $-0.15 | $-0.11 | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $0.52 | — | ||
| Q2 24 | $-0.13 | $-0.72 | ||
| Q1 24 | $-0.67 | — | ||
| Q4 23 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $840.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-561.0K | $13.1M |
| Total Assets | $34.4M | $13.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $840.5K | ||
| Q3 25 | $11.9M | — | ||
| Q2 25 | $30.4M | — | ||
| Q1 25 | $50.8M | — | ||
| Q4 24 | $79.4M | — | ||
| Q2 24 | $122.2M | $4.5M | ||
| Q1 24 | $146.5M | — | ||
| Q4 23 | $49.9M | — |
| Q4 25 | — | $13.1M | ||
| Q3 25 | $-561.0K | $14.1M | ||
| Q2 25 | $17.4M | $15.0M | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $57.0M | — | ||
| Q2 24 | $72.4M | $4.7M | ||
| Q1 24 | $67.3M | — | ||
| Q4 23 | $-17.1M | — |
| Q4 25 | — | $13.4M | ||
| Q3 25 | $34.4M | $14.3M | ||
| Q2 25 | $37.3M | $15.4M | ||
| Q1 25 | $56.9M | — | ||
| Q4 24 | $86.7M | — | ||
| Q2 24 | $127.8M | $5.1M | ||
| Q1 24 | $151.2M | — | ||
| Q4 23 | $54.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-733.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-733.1K | ||
| Q3 25 | $-18.4M | $-1.1M | ||
| Q2 25 | $-20.3M | $-716.9K | ||
| Q1 25 | $-28.6M | — | ||
| Q4 24 | $-19.5M | — | ||
| Q2 24 | $-22.6M | $-738.5K | ||
| Q1 24 | $-18.9M | — | ||
| Q4 23 | $-17.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
